Milestone Pharmaceuticals Submits Response To The FDA's CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting

Published: 2025-06-16 08:06:09 ET MIST

Published on 06/16/2025 at 08:06